This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

Not a subscriber either but will Mike be attending the AGM because I'd like to speak to him if he does..girth size apart.!

Cheers guys, big heavy weight investors?, Paul Scott, P Curtis, Goodfella etc, guess where they got there training from? LOL.

Cheers GF. Hi momentum, I was thinking of subscribing.

May do so, cheers and many thanks.

News Guys?????????????

cheers GF.

Quiet today...

MitZy, come on you know the news , whats the latest.

cheers GF

It seems to be poised to do something but is it up or down? I think up as there seems to be a pattern to the way this share performs prior to news, imho, of course.

I have had a good run on Ashtead (AHT) this year but it is now up around my target price, I know I should sell but I still think there is mileage in it. Anybody else holding????????? Any other target prices???????? Any comments

Happy trading. Rob

Hi Rob welcome to the thread. Im going to stick in there on this one as I feel news flow will push this one far higher when we actually get it.

cheers GF.

Hopefully news of phase 2 trials to be announced this week at the Agm....

What day is the AGM on Mitzy please?

cheers GF.

Weds at 11 o'clock..

Thanks for that Mitzy, if my head cold as cleared I am going and will report back.

cheers GF.

Cant make it this year GF but glad that you can..good luck.

Mitzy I will have to give it a miss. Too much under the weather with a cold.

Im sure some of the followers on the other big site will be going.

cheers GF.

Medical Marketing Int'l Group PLC
27 October 2004


FOR IMMEDIATE RELEASE 27TH OCTOBER 2004



MMI'S VIRATIS TO BE GRANTED US PATENT FOR HIV/AIDS THERAPY

Medical Marketing International Group plc (MMI) (LSE:MMG) the Cambridge,
UK-based biopharmaceutical development company focussed on cancer, AIDS and
'superbugs' announces that it has received notification of grant of the US
patent for the HIV/AIDS therapy being developed by Viratis, MMI's joint venture
with King's and Queen Mary's colleges, London.

MMI announced on 22 July 2004 that it had received notification of grant of the
European patent for the HIV/AIDS therapy and this followed an announcement on 2
April 2004 that patents had been granted in South Africa and Australia.

Viratis which is 50% owned by MMI, is developing novel ribozyme products that
block the formation of cellular receptors required for viral entry into human
cells. Studies by Viratis have already shown a high level of expression of this
ribozyme in human cells, with a corresponding reduction in viral load when
challenged with HIV.

David Best, Chairman of MMI Group, commenting on this announcement said: 'The
notification of grant of the US patent for our AIDS therapy, along with the
earlier notification of the European patent, means that we are now in a very
strong position in the two biggest markets in the world.

This news now brings Viratis in line with our cancer therapy business,
Oncosense, where we already have notification of grant for the US and European
patents for our ruthenium compounds. The next step is to bring Oncosense and
Viratis products into clinical trials'.

MMI's Annual General Meeting will take place at 11.00am today.

For further information, please contact:

David Best - Executive Chairman
MMI Group Tel: +44 (0)1223 477677

www.mmigroup.co.uk


Lisa Baderoon/Rebecca Skye Dietrich
Buchanan Communications Tel: +44 (0)20 7466 5000

lisab@buchanan.uk.com


This information is provided by RNS
The company news service from the London Stock Exchange

Strange timing on the day of the AGM....

Surprised it has not moved on this news, perhaps people are waiting for agm today.. rob

News from the AGM and what fantastic news, far more than I even expected........

Medical Marketing Int'l Group PLC
27 October 2004


FOR IMMEDIATE RELEASE 27 OCTOBER 2004



MMI


THE ANNUAL GENERAL MEETING : 2004


AND UPDATE ON PROGRESS



Medical Marketing International Group plc (MMI) (LSE:MMG) the Cambridge,
UK-based pharmaceutical development company focussed on cancer, AIDS and
'superbugs' announces that at the Annual General Meeting (AGM) of the company
held today, all resolutions were passed.


After the closing of formal proceedings David Best, Chairman of MMI made the
following statement, which included the following key highlights


6 products should be in clinical trials within 12 months

USA patent for Viratis AIDS drug to be granted (announced today)

Viratis scientists discover ribozymes to treat hepatitis

Ruthenium cancer therapy appears to have greater potential than platinum

- first ruthenium products to enter into clinical trials shortly

New funds of 2.3m secured for clinical trials - following shareholder
approval at today's AGM,

LabHotel(R) operational and first two companies operational on site

London Stock Exchange to reclassify MMI as a 'Pharmaceutical Company'


David Best further commented: '2003 was a highly successful year for MMI. We
developed and considerably strengthened our therapeutic portfolio and raised
further funds to expand our clinical programme. The year was one of transition
to not one, but a series of drugs candidates focussed on major markets and unmet
medical need. These, we perceive, could be classified as potential blockbuster
products.


The prospects for the coming year are the most exciting in the Company's
history. The DNA vaccines are already in clinical trials. Our Oncosense products
are expected to enter clinical trials in the current year and Viratis products
should follow in 2005. We are in advanced discussions concerning the broadening
of our portfolio and some of the new funding will go towards this objective as
well as the clinical trials programme.


Going forward, we are confident that we can build on and exploit the
achievements of 2003. This means increasing fundamental, long-term shareholder
value by continuing to progress our pipeline, forge even stronger relationships
with the scientific community and continue to build on the exceptional
relationships within our client base and partners, thereby creating one of the
strongest pipelines in the biopharmaceutical sector'.



For further information, please contact:

David Best - Executive Chairman
MMI Group Tel: +44 (0)1223 477677

www.mmigroup.co.uk

cheers GF.

well done GF .. very intetesting. thanks

Good news today but clinical trails is what the market wants.Imho 65-70p range until with have an annoucement on trials.